A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone

Autor: Julie Lejeune, Carole Soussain, Xavier Leleu, Brigitte Dreyfus, Caroline Dartigeas, Véronique Leblond, Stéphane Leprête, Sylvie Chevret, Marie-Sarah Dilhuidy, Anne Banos, Thérèse Aurran, Brigitte Pegourie, Olivier Tournilhac, Herve Oya, Beatrice Mahe, Bruno Anglaret, Caroline Besson, Anne Vekhoff, Pierre Morel, Maya Ouzegdouh

Publikováno v: Leukemia & lymphoma
Leukemia & lymphoma, Taylor & Francis, 2017, 58 (11), pp.2615-2623. ⟨10.1080/10428194.2017.1307357⟩
Leukemia & lymphoma, Taylor & Francis, 2017, 58 (11), pp.2615-2623. 〈10.1080/10428194.2017.1307357〉
Leukemia & lymphoma, 2017, 58 (11), pp.2615-2623. ⟨10.1080/10428194.2017.1307357⟩

In patients with advanced Waldenström macroglobulinemia (WM), overall response rate (ORR) and median progression-free survival (PFS) achieved with bortezomib alone and bortezomib rituximab combination were 27-85% and 7.9 months, and 81% and 16.4 mon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f17c36bc619884109a0b417760710e1
https://hal.archives-ouvertes.fr/hal-01655961

Bortezomib, rituximab, and risk of graft-versus-host disease (GVHD) after BEAM conditioning for allogeneic stem cell transplantation (alloSCT)

Autor: Alison M. Gulbis, Denái R. Milton, Kamal Chamoun, Elias Jabbour, Francesco Turturro, Issa F. Khouri

Publikováno v: Journal of Clinical Oncology. 35:e18543-e18543

e18543 Background: GVHD remains the main limitation of alloSCT and is exacerbated by the intensity of the conditioning regimen. In a recent study, the risk of acute grade II-IV GVHD and extensive chronic GVHD (cGVHD) after a nonmyelobaltive (NMA) reg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::950a3f17ab29f263cea258a4e797e5a3
https://doi.org/10.1200/jco.2017.35.15_suppl.e18543